IFNA1 and myasthenia gravis: Humanized anti-IFNα mAbs (Rontalizumab, developed by Genentech (San Francisco, CA, USA) and anifrolumab, developed by Medimmune (Gaithersburg, MD, USA) produced contradictory results in MG or mice model of MG (47, 48), and therefore no clinical trial in MG was conducted.